Cerus Corporation Announces New Clinical Trial to Compare Fibrinogen Treatments for Trauma Patients
I'm PortAI, I can summarize articles.
Cerus Corporation has launched a clinical trial named CRYO-FIRST to compare the efficacy of pre-thawed INTERCEPT Fibrinogen Complex (IFC) with conventional cryoprecipitated antihemophilic factor (CRYO-AHF) in trauma patients with hemorrhagic shock. The study will involve 320 patients and is funded by the U.S. Department of Defense. It aims to provide insights into early fibrinogen transfusion benefits, with results expected to inform treatment for acute trauma patients with fibrinogen deficiency.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments